Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study Academic Article uri icon

Overview

MeSH Major

  • Aminopterin
  • Drug Resistance, Neoplasm
  • Folic Acid Antagonists
  • Lymphoma, T-Cell, Peripheral
  • Neoplasm Recurrence, Local

abstract

  • To our knowledge, PROPEL (Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) is the largest prospective study conducted in patients with relapsed or refractory PTCL. Pralatrexate induced durable responses in relapsed or refractory PTCL irrespective of age, histologic subtypes, amount of prior therapy, prior methotrexate, and prior autologous stem-cell transplant. These data formed the basis for the US Food and Drug Administration approval of pralatrexate, the first drug approved for this disease.

publication date

  • March 20, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3083873

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.29.9024

PubMed ID

  • 21245435

Additional Document Info

start page

  • 1182

end page

  • 9

volume

  • 29

number

  • 9